The classical and non-classical axes of renin-angiotensin system in Parkinson disease: The bright and dark side of the moon

Ageing Research Reviews, Journal Year: 2024, Volume and Issue: 94, P. 102200 - 102200

Published: Jan. 17, 2024

Language: Английский

---

Role of uric acid in neurodegenerative diseases, focusing on Alzheimer and Parkinson disease: A new perspective

Neuropsychopharmacology Reports, Journal Year: 2024, Volume and Issue: 44(3), P. 639 - 649

Published: July 29, 2024

Abstract Neurodegenerative diseases (NDs) such as Alzheimer disease (AD) and Parkinson (PD) are group of affecting the central nervous system (CNS) characterized by progressive neurodegenerations cognitive impairment. Findings from different studies highlighted beneficial detrimental effects serum uric acid on development progression NDs. Therefore, this mini‐review aims to discuss The neuroprotective effect is mainly related antioxidant which alleviates oxidative stress‐induced neurodegeneration in AD PD. However, long‐term hyperuricemia prompts for Hyperuricemia associated with impairment dementia, gout increases dementia risk. In addition, can cause cerebral vascular injury a risk factor Taken together, relationship between NDs remains conflicting. Hence, preclinical clinical indicated regard.

Language: Английский

---

The potential role of brain renin‐angiotensin system in the neuropathology of Parkinson disease: Friend, foe or turncoat?

Journal of Cellular and Molecular Medicine, Journal Year: 2024, Volume and Issue: 28(12)

Published: June 1, 2024

Abstract Parkinson disease (PD) is one of the most common neurodegenerative diseases brain. Of note, brain renin‐angiotensin system (RAS) intricate in PD neuropathology through modulation oxidative stress, mitochondrial dysfunction and neuroinflammation. Therefore, RAS by angiotensin receptor blockers (ARBs) angiotensin‐converting enzyme inhibitors (ACEIs) may be effective reducing risk neuropathology. It has been shown that all components including peptides enzymes are present different areas. Brain plays a critical role regulation memory cognitive function, controlling central blood pressure. However, exaggerated implicated pathogenesis PD. Two well‐known pathways recognized including; classical pathway which mainly mediated AngII/AT1R detrimental effects. Conversely, non‐classical mostly ACE2/Ang1‐7/MASR AngII/AT2R beneficial effects against Exaggerated affects viability dopaminergic neurons. fundamental mechanism was not fully elucidated. Consequently, purpose this review to disclose mechanistic In addition, we try revise how ACEIs ARBs can developed for therapeutics

Language: Английский

---

Dysregulation of serotonergic neurotransmission in Parkinson disease: A key duet

European Journal of Pharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 177419 - 177419

Published: Feb. 1, 2025

Language: Английский

---

Clinical study to investigate the adjuvant role of Pentoxifylline in patients with Parkinson's disease: A randomized controlled study

International Immunopharmacology, Journal Year: 2025, Volume and Issue: 156, P. 114689 - 114689

Published: April 19, 2025

Language: Английский

---

Randomized, double-blind, placebo-controlled pilot study of metformin as an adjunctive therapy in Parkinson’s disease

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: May 2, 2025

Background Parkinson’s disease (PD) is caused by the progressive loss of dopaminergic neurons in substantia nigra. Neuroinflammation considered a key factor contributing to pathophysiology PD. Current gold-standard therapies for PD provide only symptomatic relief without slowing progression, highlighting need develop new disease-modifying treatments. Metformin has been demonstrated exert neuroprotective role several neurodegenerative disorders including Aim This study aimed clarify metformin as adjuvant therapy patients with Methods Sixty were divided into 2 groups (n = 30). Patients group 1 received levodopa/carbidopa (250/25 mg) three times daily 3 months plus placebo (Control group), while those and 500 mg two (Metformin group). assessed via Unified Disease Rating Scale (UPDRS). The serum concentrations toll like receptor 4 (TLR-4), α-synuclein, brain derived neurotropic (BDNF), high mobility box (HMGB-1) measured before after treatment. Primary outcome improvement UPDRS from baseline months. Secondary Change level biological markers. Results control did not show significant difference when compared their value Wilcoxon test ( P > 0.05), meanwhile showed treatment < 0.05). There no differences between 0.05) Man Whitney test. However, decrease TLR-4, HMGB-1, α-synuclein along statistically increase BDNF its group. any changes all markers baseline. Conclusion While scores observed groups, trends biomarker suggest potential impact adjunctive use on underlying Further studies are needed assess effects motor symptoms over longer duration. Clinical Trial Registration identifier NCT05781711.

Language: Английский

---

Faecal intestinal permeability and intestinal inflammatory markers in older adults with age-related disorders: a systematic review and meta-analysis

Ageing Research Reviews, Journal Year: 2024, Volume and Issue: unknown, P. 102506 - 102506

Published: Sept. 1, 2024

Language: Английский

---

Repurposing celecoxib as adjuvant therapy in patients with Parkinsonian disease: a new therapeutic dawn: randomized controlled pilot study

Inflammopharmacology, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 28, 2024

Language: Английский

---

Synergistic effect of probiotics and postbiotics on reducing cytokine storm, lung dysfunction, and immune escape phenomenon caused by SARS-CoV-2 infection

Food Bioscience, Journal Year: 2024, Volume and Issue: 63, P. 105617 - 105617

Published: Dec. 7, 2024

Language: Английский

---